Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SAFESCIMET

Financiado

Cerrado

European Modular Education and Training Programme in Safety Sciences for Medicin...

European Modular Education and Training Programme in Safety Sciences for Medicines Background: In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA h... ver más

30/09/2016

F. HoffmannLa Roch...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

F. HoffmannLa Roche AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 31 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-09-30 No tenemos la información de la convocatoria

0% 40% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

31 Participantes

F. HoffmannLa Roche AG

0.00€ | Lider

Novo Nordisk

N.D. | Participante

Eli Lilly

N.D. | Participante

SURREY

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAFESCIMET European Modular Education and Training Programme in Safety... 6M€ Cerrado

PEARRL Pharmaceutical Education And Research with Regulatory Links... 4M€ Cerrado

More-EUROPA More Effectively Using Registries to suppOrt PAtient-centere... 7M€ Cerrado

ERAMET Ecosystem for rapid adoption of modelling and simulation MET... 4M€ Cerrado

PROTECT Pharmacoepidemiolocal Research on Outcomes of Therapeutics b... 29M€ Cerrado

ConcePTION Building an ecosystem for better monitoring and communicatin... 29M€ Cerrado

Líder del proyecto

F. HoffmannLa Roche AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Background: In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objectives: We present a new and unique pan-European education and training network, which solves this shortfall by developing and establishing a comprehensive modular Education and Training Programme in Safety Sciences for Medicines (SafeSciMET). This programme will fulfil the needs of pharmaceutical industry, regulatory authorities and academia. The network, consisting of top institutes for drug safety education and research, proposes a new type, high quality and sustainable programme for education and training in Safety Sciences for Medicines (S2M). The tailor-made training modules will encompass the safety, ethical, regulatory and societal aspects in all phases of drug development, with emphasis on integrative, translational and 3Rs aspects of drug safety assessment. Individual safety professionals who wish to address specific knowledge gaps will be able to follow single modules. The modular set up also provides an excellent opportunity for following dedicated sub-sets of modules, to be accredited for Continuing Professional Development (CPD). Scientists successfully completing the full programme, including an integrative MSc-thesis, will be awarded with an accredited Master of Advanced Safety Sciences of Medicines (M4S2M). All training modules and procedures will be aligned with the Bologna process. Principle learning outcomes are novel competences in translational safety sciences, leading to safety scientists who are able to perform holistic and critical evaluations of the safety of drug candidates and new medicines by linking of animal and patient data.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores